1. Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER)
- Author
-
Luis-Emilio Garcia-Perez, Karen G. Malley, Karin S. Coyne, Ryan T. Hietpas, Jessica B Jordan, Katie D. Stewart, Paula Wullenweber, Qianqian Wang, Maria Yu, Katelyn N. Cutts, Kristina S. Boye, Brooke M. Currie, Louis S. Matza, and K. Jack Ishak
- Subjects
Male ,medicine.medical_specialty ,Recombinant Fusion Proteins ,Endocrinology, Diabetes and Metabolism ,Training time ,Glucagon-Like Peptides ,030209 endocrinology & metabolism ,Type 2 diabetes ,030204 cardiovascular system & hematology ,Health outcomes ,03 medical and health sciences ,injection devices ,0302 clinical medicine ,Endocrinology ,dulaglutide ,Internal Medicine ,medicine ,Humans ,Hypoglycemic Agents ,crossover study ,preference ,Cross-Over Studies ,semaglutide ,business.industry ,Semaglutide ,Patient Preference ,Original Articles ,Middle Aged ,medicine.disease ,Crossover study ,Patient preference ,Immunoglobulin Fc Fragments ,Injection device ,Diabetes Mellitus, Type 2 ,Physical therapy ,Female ,Original Article ,Dulaglutide ,type 2 diabetes ,business ,medicine.drug - Abstract
Aim When selecting treatments for type 2 diabetes (T2D), it is important to consider not only efficacy and safety, but also other treatment attributes that have an impact on patient preference. The objective of this study was to examine preference between injection devices used for two weekly GLP‐1 receptor agonists. Materials and Methods The PREFER study was an open‐label, multicentre, randomized, crossover study assessing patient preference for dulaglutide and semaglutide injection devices among injection‐naïve patients receiving oral medication for type 2 diabetes. After being trained to use each device, participants performed all steps of injection preparation and administered mock injections into an injection pad. Time‐to‐train (TTT) for each device was assessed in a subset. Results There were 310 evaluable participants (48.4% female; mean age, 60.0 years; 78 participants in the TTT subgroup). More participants preferred the dulaglutide device than the semaglutide device (84.2% vs. 12.3%; P
- Published
- 2019